SPOTLIGHT -
February 8th 2024
Phase 3 study reveals exebacase combined with standard antibiotics in treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis did not meet its primary endpoints.
May 20th 2021
Rates of in-hospital mortality and days with bacteremia were similar between the two study cohorts.
June 11th 2020
The antibacterial is efficacious in a majority of patients in a small study.
February 19th 2020
The MRSA infection investigation was halted by the data and safety monitoring board due to concerns over acute kidney injury.
February 14th 2020
Therapy options have increased in recent decades, yet there is a lack of guidance.